Is Compounded Tirzepatide Still Legal in 2026? The Rules, Explained
Yes, with conditions. Mass-produced copies ended when the FDA shortage exception closed, but state-licensed 503A pharmacies may still compound tirzepatide for an individual patient when a physician documents a clinical reason a commercially available product does not meet that patient's needs.
Reviewed by board-certified physicians · Published 2026-08-28 · Updated 2026-08-28 · 9 min read
Key facts
Tirzepatide came off the FDA drug shortage list in December 2024, and a federal court declined to block that decision in 2025.
The shortage exception that allowed large-scale copying of the branded products is over.
State-licensed 503A compounding pharmacies may still prepare tirzepatide for a specific patient under a physician's individualized prescription with a documented clinical need.
The FDA sent waves of warning letters to GLP-1 compounders and marketers in September 2025, February 2026, and June 2026, aimed mostly at marketing claims and mass production.
Compounded tirzepatide is not FDA-approved. That has always been true of every compounded medication.
What changed between 2024 and 2026?
During the tirzepatide shortage, federal law allowed compounding pharmacies to prepare what were essentially copies of the branded products, because patients could not reliably fill prescriptions for Zepbound® or Mounjaro®. In December 2024 the FDA determined the shortage was resolved. A compounding trade group sued to reverse that determination, and in 2025 a federal court declined to block the FDA's decision.
With the shortage exception closed, the legal basis for mass-producing tirzepatide copies disappeared. Semaglutide followed the same path in 2025, which is why so many telehealth sellers of compounded GLP-1 products changed their offerings or shut down during 2025 and 2026.
So how can any pharmacy still compound tirzepatide?
Compounding did not become illegal. It returned to its normal rules. Under section 503A of the federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare a medication for a specific, named patient when a licensed prescriber writes an individualized prescription, and when the compounded formulation is not essentially a copy of a commercially available drug.
In practice, that means the prescription needs a documented clinical reason the commercial product does not meet that patient's needs. Examples the FDA itself has cited include a different dosage form or a strength a manufacturer does not sell. What does not qualify on its own is price or convenience. A prescription written only because the compounded version costs less sits outside what 503A permits.
Whether a given prescription qualifies is a judgment made prescription by prescription, by the prescribing physician and the dispensing pharmacy. That is why legitimate platforms route every patient through a physician evaluation rather than selling vials from a menu.
What is 'personalized dosing,' and does it make compounding legal?
After the shortage ended, some sellers began marketing tirzepatide at strengths slightly different from the branded pens and calling it personalized. Regulators have looked hard at this. The FDA's position is that a trivial change made to evade the essentially-a-copy rule does not create a valid clinical need, while a genuine, documented, patient-specific reason for a different strength or dosage form can.
The plain summary for patients: the label 'personalized' by itself proves nothing. What matters is whether a licensed physician evaluated you and documented why a commercially available product was not appropriate for you specifically.
3/mo CHROMA23+ Membership unlocks it at one clear price, medication priced separately and always shown.
Beginning in September 2025 the FDA, joined at times by the FTC, sent enforcement letters to dozens of compounders, telehealth marketers, and ingredient sellers. Further waves followed in February 2026 and June 2026. The letters focused on a few recurring problems: continuing to mass-produce copies after the shortage ended, marketing compounded products with claims that they are FDA-approved or equivalent to branded drugs, selling research-grade powders to consumers, and safety claims no compounded product may make.
The pattern matters for patients. Enforcement has been aimed primarily at how products are made at scale and how they are marketed, not at the existence of physician-directed, patient-specific compounding, which remains a lawful part of pharmacy practice in every state.
How do I know if a pharmacy or platform is operating legitimately?
A few checks separate licensed pharmacy practice from the gray market that grew during the shortage:
A licensed physician evaluates you before any prescription exists. If a site sells a vial without a prescription, it is not a pharmacy transaction at all.
The dispensing pharmacy is a state-licensed compounding pharmacy you can verify through the state board of pharmacy.
The product is dispensed under a prescription in your name, with the strength, beyond-use date, and pharmacy details on the label.
Nobody claims the compounded product is FDA-approved, because no compounded medication is.
'Research use only' peptides, powders for reconstitution sold without a prescription, and international mail-order sellers sit outside the regulated system entirely. FDA adverse event reports connected to compounded GLP-1 products have come disproportionately from unregulated sources and dosing errors.
What happens to patients whose supplier shut down?
If your previous telehealth provider or pharmacy stopped offering compounded tirzepatide, you have three broad paths: move to the branded products through insurance, move to the manufacturers' direct self-pay programs, or be evaluated by a physician to determine whether a patient-specific compounded prescription remains clinically appropriate for you. Which path fits depends on your coverage, your dose, and your clinical picture, which is a conversation with a physician, not a checkout decision.
Whatever you do, avoid the two common mistakes of 2025: stockpiling vials past their beyond-use dates, and moving to unregulated sellers to keep a price. Both trade a legal question for a safety problem.
Frequently asked questions
Is compounded tirzepatide FDA-approved?
No. No compounded medication is FDA-approved. FDA approval attaches to specific branded products such as Zepbound® and Mounjaro®. Compounded tirzepatide is prepared under state pharmacy law and federal 503A rules instead, which is a different framework with different safeguards.
Did the courts ban compounded tirzepatide?
No. The court decisions upheld the FDA's finding that the shortage ended, which closed the exception that allowed copying the branded products at scale. Patient-specific compounding under 503A was not banned and continues under its usual rules.
Can I still get semaglutide from a compounding pharmacy?
Broadly no. The semaglutide shortage was declared resolved in 2025, and the same essentially-a-copy rules now apply. CHROMA23® does not offer compounded semaglutide; its compounded GLP-1 offering is tirzepatide only, prescribed patient by patient.
Is it legal for me, the patient, to possess compounded tirzepatide?
Dispensed under a valid prescription from a licensed pharmacy, yes. Enforcement in this area targets manufacturers, marketers, and sellers operating outside the rules, not patients filling legitimate prescriptions.
Will compounded tirzepatide disappear entirely?
Nobody can promise a regulatory future. The current framework allows patient-specific compounding with documented clinical need, and that framework has held through every enforcement wave so far. A physician evaluation is the reliable way to learn what is available for your situation at any given time.
About CHROMA23®
CHROMA23® is a clinical weight loss platform built on prescription protocols: injectables, oral medicine, and the protocols that come next, under one 3 membership. Every prescription decision is made by an independent, board-certified physician licensed in the patient's state, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. The membership is 3. The medicine is real. The physician is real.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Always consult a board-certified physician about your individual situation. Figures from named clinical trials describe study populations; individual results vary and are not typical.